Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens

Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 405 · see citing works

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

Donnelly, J., Medini, D., Boccadifuoco, G., Biolchi, A., Ward, J. I., Frasch, C. E., Moxon, E. R., Stella, M., Comanducci, M., Bambini, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013758107 · Cited by 296 · see citing works

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

Vogel, U. F., Taha, M., Vázquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 283 · see citing works

Estimation of Vaccine Effectiveness Using the Screening Method

Farrington, P. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.4.742 · Cited by 261 · see citing works

Advances in the Development of Vaccines againstNeisseria meningitidis

Tan, L., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233 · see citing works

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Cartwright, K. A. V., Morris, R., Rümke, H. C., Fox, A., Borrow, R., Begg, N. T., Richmond, P., & POOLMAN, J. T. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00044-4 · Cited by 176 · see citing works

Meningococcal C conjugate vaccine: the experience in England and Wales

Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168 · see citing works

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study

Christensen, H., Trotter, C. L., Hickman, M., & Edmunds, W. J. (2014) · BMJ · doi:10.1136/bmj.g5725 · Cited by 142 · see citing works

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

Frosi, G., Biolchi, A., Sapio, M. L., Rigat, F., Gilchrist, S., Lucidarme, J., Findlow, J., Borrow, R., Pizza, M., Giuliani, M. M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.006 · Cited by 137 · see citing works

Bexsero® chronicle

Vernikos, G. S., & Medini, D. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000162 · Cited by 104 · see citing works

Enter B and W: two new meningococcal vaccine programmes launched

Ladhani, S. N., Ramsay, M. E., Borrow, R., Riordan, A. I., Watson, J. M., & Pollard, A. J. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308928 · Cited by 103 · see citing works

Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015

Campbell, H. J., Saliba, V., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2015) · Eurosurveillance · doi:10.2807/1560-7917.es2015.20.28.21188 · Cited by 96 · see citing works

Immunogenicity of a Meningococcal B Vaccine during a University Outbreak

Basta, N. E., Mahmoud, A. A. F., Wolfson, J. A., Ploß, A., Heller, B. L., Hanna, S., Johnsen, P., Izzo, R., Grenfell, B. T., Findlow, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514866 · Cited by 73 · see citing works

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

Brunelli, B., Tordello, E. D., Palumbo, E., Biolchi, A., Bambini, S., Comanducci, M., Muzzi, A., Pizza, M., Rappuoli, R., Donnelly, J., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.064 · Cited by 51 · see citing works

Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme

Tirani, M., Meregaglia, M., & Melegaro, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123383 · Cited by 40 · see citing works

Invasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources

Ladhani, S. N., Waight, P. A., Ribeiro, S., & Ramsay, M. E. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1247-7 · Cited by 22 · see citing works

The Role of Pediatricians as Key Stakeholders in Influencing Immunization Policy Decisions for the Introduction of Meningitis B Vaccine in Canada: The Ontario Perspective

Yamashiro, H., Cutcliffe, N., Dobson, S., Fisman, D. N., & Gold, R. (2015) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2015/963940 · Cited by 8 · see citing works

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

Parikh, S. R., Campbell, H. J., Bettinger, J. A., Harrison, L. H., Marshall, H. S., Martinón‐Torres, F., Sáfadi, M. A. P., Shao, Z., Zhu, B., von Gottberg, A., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.079 · Cited by 290 · see citing works

Technologies to address antimicrobial resistance

Baker, S. J., Payne, D. J., Rappuoli, R., & Gregorio, E. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717160115 · Cited by 219 · see citing works

Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

López‐Lacort, M., Muñoz-Quiles, C., Mira‐Iglesias, A., López‐Labrador, F. X., Mengual‐Chuliá, B., Fernández-García, C., Carballido‐Fernández, M., Caplliure, A. P., Mollar‐Maseres, J., Shalabi-Benavent, M. J., et al. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.6.2400046 · Cited by 216 · see citing works

Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

Ladhani, S. N., Andrews, N. J., Parikh, S. R., Campbell, H. J., White, J. M., Edelstein, M. L., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901229 · Cited by 215 · see citing works

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Acevedo, R., Bai, X., Borrow, R., Caugant, D. A., Carlos, J., Ceyhan, M., Christensen, H., Climent, Y., Wals, P. D., Dinleyici, E. Ç., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1557520 · Cited by 194 · see citing works

The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology

Masignani, V., Pizza, M., & Moxon, E. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00751 · Cited by 168 · see citing works

Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study

Bertran, M., Andrews, N. J., Davison, C., Dugbazah, B., Boateng, J. O., Lunt, R., Hardstaff, J., Green, M., Blomquist, P. B., Turner, C., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00057-9 · Cited by 155 · see citing works

Vaccines against Meningococcal Diseases

Pizza, M., Bekkat-Berkani, R., & Rappuoli, R. (2020) · Microorganisms · doi:10.3390/microorganisms8101521 · Cited by 150 · see citing works

Update on community-acquired bacterial meningitis: guidance and challenges

van Ettekoven, C. N., van de Beek, D., & Brouwer, M. C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.04.019 · Cited by 116 · see citing works

Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy

Long, Q., Zheng, P., Zheng, X. W., Li, W., Hua, L., Yang, Z., Huang, W., & Ma, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114321 · Cited by 114 · see citing works

A Vaccine Against Group B Streptococcus: Recent Advances

Carreras‐Abad, C., Ramkhelawon, L., Heath, P. T., & Doaré, K. L. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s203454 · Cited by 112 · see citing works

Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study

Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Almond, S., Beazley, R., Mitchell, J., Lally, N., Ahoure, M., Denehy, E., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00754-4 · Cited by 105 · see citing works

Epidemiology of community-acquired bacterial meningitis

Brouwer, M. C., & van de Beek, D. (2017) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000417 · Cited by 99 · see citing works

Restricted fluid bolus volume in early septic shock: results of the Fluids in Shock pilot trial

Inwald, D. P., Canter, R. R., Woolfall, K., Mouncey, P. R., Zenasni, Z., O’Hara, C., Carter, A., Jones, N., Lyttle, M. D., Nadel, S., et al. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-314924 · Cited by 98 · see citing works

Meningococcal B vaccine (4CMenB): the journey from research to real world experience

Rappuoli, R., Pizza, M., Masignani, V., & Vadivelu, K. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1547637 · Cited by 93 · see citing works

Invasive Meningococcal Disease in the Vaccine Era

Nadel, S., & Ninis, N. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00321 · Cited by 90 · see citing works

Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis

Pormohammad, A., Abasi, E., Azimi, T., Hosseini, S. S., Safari, H., Nasiri, M. J., & Fooladi, A. A. I. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103571 · Cited by 88 · see citing works

Progress toward the global control of Neisseria meningitidis : 21st century vaccines, current guidelines, and challenges for future vaccine development

Dretler, A. W., Rouphael, N., & Stephens, D. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451810 · Cited by 87 · see citing works

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide

Muzzi, A., Brozzi, A., Serino, L., Bodini, M., Abad, R., Caugant, D. A., Comanducci, M., de Lemos, A. P. S., Gorla, M. C., Křížová, P., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.061 · Cited by 87 · see citing works

Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015–2016

Campbell, H. J., Edelstein, M. L., Andrews, N. J., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2017) · Emerging infectious diseases · doi:10.3201/eid2307.170236 · Cited by 85 · see citing works

Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative

Aye, A. M. M., Bai, X., Borrow, R., Bory, S., Carlos, J., Caugant, D. A., Chiou, C., Dai, V. T. T., Dinleyici, E. Ç., Ghimire, P., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.07.025 · Cited by 81 · see citing works

First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

Ladhani, S. N., Campbell, H. J., Andrews, N. J., Parikh, S. R., White, J. M., Edelstein, M. L., Clark, S. A., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1244 · Cited by 80 · see citing works

Impact of meningococcal group B OMV vaccines, beyond their brief

Petousis‐Harris, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1381810 · Cited by 80 · see citing works

Meningococcal disease, a clinical and epidemiological review

Siqueira‐Batista, R., Gomes, A. P., Gazineo, J. L. D., Miguel, P. S. B., Santana, L. A., Oliveira, L., & Geller, M. (2017) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2017.10.004 · Cited by 75 · see citing works

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada

Wals, P. D., Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Law, D. K. S., Serres, G. D., Gîlca, V., Gilca, R., & Boulianne, N. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix154 · Cited by 74 · see citing works

Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children

Castilla, J., Cenoz, M. G., Abad, R., Sánchez-Cambronero, L., Lorusso, N., Izquierdo, C., Llabrés, S. C., Roig, J., Malvar, A., Carril, F. G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206433 · Cited by 71 · see citing works

Meningococcal disease in the Middle East and Africa: Findings and updates from the Global Meningococcal Initiative

Borrow, R., Caugant, D. A., Ceyhan, M., Christensen, H., Dinleyici, E. Ç., Findlow, J., Glennie, L., von Gottberg, A., Kechrid, A., Moreno, J. V., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.04.007 · Cited by 68 · see citing works

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Azzari, C., Moriondo, M., Nieddu, F., Guarnieri, V., Lodi, L., Canessa, C., Indolfi, G., Giovannini, M., Napoletano, G., Russo, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8030469 · Cited by 68 · see citing works

Serocorrelates of protection against infant group B streptococcus disease

Doaré, K. L., Kampmann, B., Vekemans, J., Heath, P. T., Goldblatt, D., Nahm, M. H., Baker, C. J., Edwards, M. S., Kwatra, G., Andrews, N. J., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30659-5 · Cited by 68 · see citing works

Emerging experience with meningococcal serogroup B protein vaccines

Toneatto, D., Pizza, M., Masignani, V., & Rappuoli, R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1308828 · Cited by 67 · see citing works

Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and quantitative assessment

Parikh, S. R., Newbold, L. S., Slater, S., Stella, M., Moschioni, M., Lucidarme, J., Paola, R. D., Giuliani, M., Serino, L., Gray, S. J., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30170-6 · Cited by 66 · see citing works

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Rodrigues, F. M. P., Marlow, R. D., Simões, M. J., Danon, L., Ladhani, S. N., & Finn, A. H. R. (2020) · JAMA · doi:10.1001/jama.2020.20449 · Cited by 63 · see citing works

Proteome‐minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform

Zanella, I., König, E., Tomasi, M., Gagliardi, A., Frattini, L. F., Fantappiè, L., Irene, C., Zerbini, F., Caproni, E., Isaac, S. J., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12066 · Cited by 63 · see citing works

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis

Flacco, M. E., Manzoli, L., Rosso, A., Marzuillo, C., Bergamini, M., Stefanati, A., Cultrera, R., Villari, P., Ricciardi, W., Ioannidis, J. P. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30048-3 · Cited by 62 · see citing works

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch

Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Betala-Belinga, J.-F., Serres, G. D., & Wals, P. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.021 · Cited by 62 · see citing works

Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study

Bryan, P. T., Seabroke, S., Wong, J., Donegan, K. L., Webb, E., Goldsmith, C., Vipond, C., & Feavers, I. M. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30103-2 · Cited by 61 · see citing works

Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)

Li, J., Shao, Z., Liu, G., Bai, X., Borrow, R., Chen, M., Guo, Q., Han, Y., Li, Y., Taha, M., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.01.007 · Cited by 59 · see citing works

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017)

Ladhani, S. N., Campbell, H. J., Lucidarme, J., Gray, S. J., Parikh, S. R., Willerton, L., Clark, S. A., Lekshmi, A., Walker, A., Patel, S. R., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4146-5 · Cited by 58 · see citing works

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines

Villena, R., Sáfadi, M. A. P., Valenzuela, M. T., Torres, J. P., Finn, A. H. R., & O’Ryan, M. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1458175 · Cited by 58 · see citing works

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations

Vekemans, J., Crofts, J., Baker, C. J., Goldblatt, D., Heath, P. T., Madhi, S. A., Doaré, K. L., Andrews, N. J., Pollard, A. J., Saha, S. K., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.039 · Cited by 58 · see citing works

4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation

Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Almond, S., Beazley, R., Mitchell, J., Ahoure, M., Denehy, E., Flood, L., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.05.021 · Cited by 57 · see citing works

The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review

Yezli, S. (2018) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2018.05.003 · Cited by 57 · see citing works

Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine

Nolan, T. M., Santolaya, M. E., de Looze, F. J., Marshall, H. S., Richmond, P., Henein, S., Rheault, P., Heaton, K., Perrett, K. P., Garfield, H., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2018.12.059 · Cited by 52 · see citing works

A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines

Findlow, J., Balmer, P., & Borrow, R. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1593082 · Cited by 51 · see citing works

Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial

Martinón‐Torres, F., Sáfadi, M. A. P., Martínez, A. C., Marquez, P. I., Torres, J. C. T., Weckx, L. Y., Moreira, E. D., Mensi, I., Calabresi, M., & Toneatto, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.023 · Cited by 50 · see citing works

A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health

Biselli, R., Nisini, R., Lista, F. R., Autore, A., Lastilla, M., Lorenzo, G. D., Peragallo, M. S., Stroffolini, T., & D’Amelio, R. (2022) · Biomedicines · doi:10.3390/biomedicines10082050 · Cited by 48 · see citing works

Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010–2015

Parikh, S. R., Campbell, H. J., Gray, S. J., Beebeejaun, K., Ribeiro, S., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.038 · Cited by 47 · see citing works

Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK

Ladhani, S. N., White, P. J., Campbell, H. J., Mandal, S., Borrow, R., Andrews, N. J., Bhopal, S., Saunders, J., Mohammed, H. P., Drisdale-Gordon, L., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00031-8 · Cited by 46 · see citing works

Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States

Rajam, G., Stella, M., Kim, E., Paulos, S., Boccadifuoco, G., Serino, L., Carlone, G. M., & Medini, D. (2017) · mSphere · doi:10.1128/msphere.00261-17 · Cited by 46 · see citing works

Inhibitors of the Neisseria meningitidis PilF ATPase provoke type IV pilus disassembly

Aubey, F., Corre, J., Kong, Y., Xu, X., Obino, D., Goussard, S., Lapeyrere, C., Souphron, J., Couturier, C., Renard, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817757116 · Cited by 46 · see citing works

Herd Protection against Meningococcal Disease through Vaccination

Clark, S. A., & Borrow, R. (2020) · Microorganisms · doi:10.3390/microorganisms8111675 · Cited by 45 · see citing works

Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination

Archer, B. N., Chiu, C. K., Jayasinghe, S. H., Richmond, P., McVernon, J., Lahra, M. M., Andrews, R. M., & McIntyre, P. B. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01340 · Cited by 44 · see citing works

Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination

Martinón‐Torres, F., Banzhoff, A., Azzari, C., Wals, P. D., Marlow, R. D., Marshall, H. S., Pizza, M., Rappuoli, R., & Bekkat-Berkani, R. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.031 · Cited by 42 · see citing works

Vaccination strategies for the prevention of meningococcal disease

Vuocolo, S. C., Balmer, P., Gruber, W. C., Jansen, K. U., Anderson, A. S., Perez, J. L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451287 · Cited by 42 · see citing works

Vaccine Evolution and Its Application to Fight Modern Threats

Andreano, E., D’Oro, U., Rappuoli, R., & Finco, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01722 · Cited by 41 · see citing works

Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Bai, X., Borrow, R., Bukovski, S., Caugant, D. A., Culic, D., Delic, S., Dinleyici, E. Ç., Eloshvili, M., Erdősi, T., Galajeva, J., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.018 · Cited by 41 · see citing works

Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria

Sadarangani, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02674 · Cited by 39 · see citing works

Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis

Xu, J., Chen, Y., Yue, M., Yu, J., Han, F., Xu, L., & Shao, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2071077 · Cited by 37 · see citing works

Recent Progress in the Prevention of Serogroup B Meningococcal Disease

Feavers, I. M., & Maiden, M. C. J. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00566-16 · Cited by 36 · see citing works

Human genetics of meningococcal infections

Hodeib, S., Herberg, J. A., Levin, M., & Sancho‐Shimizu, V. (2020) · Human Genetics · doi:10.1007/s00439-020-02128-4 · Cited by 36 · see citing works

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study

Welsch, J. A., Senders, S. D., Essink, B. J., Klein, T., Smolenov, I. V., Pedotti, P., Barbi, S., Verma, B., & Toneatto, D. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.016 · Cited by 35 · see citing works

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B

Calle, I. R., Raguindin, P. F., Rial, J. G., Rodrı́guez-Tenreiro, C., & Martinón‐Torres, F. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s159952 · Cited by 34 · see citing works

Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience

Isitt, C. E., Cosgrove, C. A., Ramsay, M. E., & Ladhani, S. N. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-318047 · Cited by 34 · see citing works

The Use of Quasi-experimental Designs for Vaccine Evaluation

Bernal, J. L., Andrews, N. J., & Amirthalingam, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy906 · Cited by 33 · see citing works

Monocyte-activation test to reliably measure the pyrogenic content of a vaccine: An in vitro pyrogen test to overcome in vivo limitations

Valentini, S. B., Santoro, G., Baffetta, F., Franceschi, S., Paludi, M., Brandini, E., Gherardini, L., Serruto, D., & Capecchi, B. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.082 · Cited by 33 · see citing works

Monitoring the COVID-19 immunisation programme through a national immunisation Management system – England’s experience

Tessier, E., Stowe, J., Tsang, C., Rai, Y., Clarke, E., Lakhani, A., Makwana, A., Heard, H., Rickeard, T., Kirsebom, F., et al. (2022) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2022.104974 · Cited by 32 · see citing works

Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial

Martinón‐Torres, F., Martínez, A. C., Simkó, R., Marquez, P. I., Arimany, J.-L., Giménez‐Sánchez, F., Gianzo, J. A. C., Kovacs, E. M. R., Rojo, P., Wang, H., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.12.005 · Cited by 31 · see citing works

Engineered Remolding and Application of Bacterial Membrane Vesicles

Li, Q., Rao, Y., Zhu, K., Rao, X., & Zhou, R. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.729369 · Cited by 30 · see citing works

Critical care management of infectious meningitis and encephalitis

Meyfroidt, G., Kurtz, P., & Sonneville, R. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05901-w · Cited by 29 · see citing works

Invasive Meningococcal Disease, 2011–2020, and Impact of the COVID-19 Pandemic, England

Subbarao, S., Campbell, H. J., Ribeiro, S., Clark, S. A., Lucidarme, J., Ramsay, M. E., Borrow, R., & Ladhani, S. N. (2021) · Emerging infectious diseases · doi:10.3201/eid2709.204866 · Cited by 29 · see citing works

B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of Neisseria meningitidis in adolescents

Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A. J., MacLennan, J. M., Maiden, M. C. J., Ramsay, M. E., Ladhani, S. N., Trotter, C. L., Borrow, R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020988 · Cited by 28 · see citing works

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

Martinón‐Torres, F., Nolan, T. M., Toneatto, D., & Banzhoff, A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1627159 · Cited by 28 · see citing works

The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae

Rubin, D. H. F., Ross, J. D. C., & Grad, Y. H. (2020) · Translational research · doi:10.1016/j.trsl.2020.02.002 · Cited by 27 · see citing works

Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea

Haese, E. C., Thai, V. C., & Kahler, C. M. (2021) · Vaccines · doi:10.3390/vaccines9070804 · Cited by 27 · see citing works

Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults

Leeds, I. L., Namasivayam, V., Bamogo, A., Sankhla, P., & Thayer, W. M. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.09.020 · Cited by 27 · see citing works

Correlates of protection for meningococcal surface protein vaccines: lessons from the past

Findlow, J., Lucidarme, J., Taha, M., Burman, C., & Balmer, P. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1940144 · Cited by 25 · see citing works

First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia

Marshall, H. S., Lally, N., Flood, L., & Phillips, P. A. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50481 · Cited by 25 · see citing works

Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine

Lujan, E., Partridge, E., Giuntini, S., Ram, S., & Granoff, D. M. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00121-17 · Cited by 24 · see citing works

Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK

Ladhani, S. N., Andrews, N. J., & Ramsay, M. E. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30492-8 · Cited by 24 · see citing works

A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB)

Marshall, G. S., Abbing‐Karahagopian, V., Marshall, H. S., Cenci, S., Conway, J. H., Occhipinti, E., Bekkat-Berkani, R., Banzhoff, A., & Sohn, W.-Y. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2222015 · Cited by 24 · see citing works

Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus

Lujan, E., Winter, K., Rovaris, J., Liu, Q., & Granoff, D. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix519 · Cited by 24 · see citing works

Genomic Surveillance of 4CMenB Vaccine Antigenic Variants among Disease-Causing Neisseria meningitidis Isolates, United Kingdom, 2010–2016

Rodrigues, C. M. C., Lucidarme, J., Borrow, R., Smith, A. H., Cameron, J. C., Moxon, E. R., & Maiden, M. C. J. (2018) · Emerging infectious diseases · doi:10.3201/eid2404.171480 · Cited by 24 · see citing works

Neisseria meningitidis and meningococcal disease: recent discoveries and innovations

Read, R. C. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000606 · Cited by 24 · see citing works

Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population

Stejskal, L., Thistlethwaite, A., Bencomo, F. R., Rashmi, S., Harrison, O. B., Feavers, I. M., Maiden, M. C. J., Jerse, A. E., Barnes, G., Chirro, O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51053-x · Cited by 23 · see citing works

Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices

Sohn, W.-Y., Tahrat, H., Novy, P., & Bekkat-Berkani, R. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2021881 · Cited by 23 · see citing works

Psychological interventions as vaccine adjuvants: A systematic review

Vedhara, K., Ayling, K., Sunger, K., Caldwell, D. M., Halliday, V., Fairclough, L. C., Avery, A. J., Robles, L. A., Garibaldi, J. M., Welton, N. J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.091 · Cited by 23 · see citing works

The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies

Bonanni, P., Villani, A., Scotti, S., Biasci, P., Russo, R., Maio, T., Rosati, G. V., Moscadelli, A., Conforti, G., Azzari, C., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.019 · Cited by 23 · see citing works

Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp

López‐Sagaseta, J., Beernink, P. T., Bianchi, F., Santini, L., Frigimelica, E., Lucas, A. H., Pizza, M., & Bottomley, M. J. (2018) · Nature Communications · doi:10.1038/s41467-018-02827-7 · Cited by 23 · see citing works

Challenges and opportunities for meningococcal vaccination in the developing world

Shaker, R., Fayad, D., & Dbaibo, G. S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1434463 · Cited by 22 · see citing works

Trends in laboratory-confirmed bacterial meningitis (2012–2019): national observational study, England

Subbarao, S., Ribeiro, S., Campbell, H. J., Okike, I. O., Ramsay, M. E., & Ladhani, S. N. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100692 · Cited by 22 · see citing works

Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines

Baarda, B. I., Martinez, F. G., & Sikora, A. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02793 · Cited by 22 · see citing works

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials

Zafack, J. G., Bureau, A., Skowronski, D. M., & Serres, G. D. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026953 · Cited by 22 · see citing works

TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines

Martinón‐Torres, F., Bosch, X. F., Rappuoli, R., Ladhani, S. N., Redondo, E., Vesikari, T., García‐Sastre, A., Calle, I. R., Rial, J. G., Salas, A., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1609823 · Cited by 21 · see citing works

NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies

Liguori, A., Iacono, L. D., Maruggi, G., Benucci, B., Merola, M., Surdo, P. L., López‐Sagaseta, J., Pizza, M., Malito, E., & Bottomley, M. J. (2018) · mBio · doi:10.1128/mbio.01914-18 · Cited by 21 · see citing works

Evaluating the Effectiveness of Vaccines Using a Regression Discontinuity Design

Basta, N. E., & Halloran, M. E. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz043 · Cited by 21 · see citing works

Using Omics Technologies and Systems Biology to Identify Epitope Targets for the Development of Monoclonal Antibodies Against Antibiotic-Resistant Bacteria

Martín-Galiano, A. J., & McConnell, M. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02841 · Cited by 21 · see citing works

Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates

Sempere, J., Llamosí, M., Menéndez, I. D. R., Ruiz, B. L., Domenech, M., & González‐Camacho, F. (2021) · Vaccines · doi:10.3390/vaccines9020181 · Cited by 21 · see citing works

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries

Doaré, K. L., Benassi, V., Cavaleri, M., Enwere, G., Giersing, B. K., Goldblatt, D., Heath, P. T., Hombach, J., Isbrucker, R. A., Karampatsas, K., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127131 · Cited by 20 · see citing works

Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study

Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Beazley, R., Almond, S., Lally, N., Bell, C., Flood, L., Ward, J. S., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf372 · Cited by 20 · see citing works

Four-Component Recombinant Protein–Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy

Lodi, L., Barbati, F., Amicizia, D., Baldo, V., Barbui, A. M., Bondi, A., Costantino, C., Dalt, L. D., Ferrara, L., Fortunato, F., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29678 · Cited by 20 · see citing works

Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

Ladhani, S. N., Andrews, N. J., Parikh, S. R., Campbell, H. J., White, J. M., Edelstein, M. L., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901229 · Cited by 215 · see citing works

Outcomes of Serogroup B Meningococcal Disease in Children after Implementation of Routine Infant 4cmenb Vaccination; Active Prospective National Surveillance, September 2015 - March 2021, England

Mensah, A. A., Campbell, H. J., Clark, S. A., Ribeiro, S., Lucidarme, J., Bai, X., Borrow, R., & Ladhani, S. N. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00379-0 · Cited by 18 · see citing works

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Azzari, C., Moriondo, M., Nieddu, F., Guarnieri, V., Lodi, L., Canessa, C., Indolfi, G., Giovannini, M., Napoletano, G., Russo, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8030469 · Cited by 68 · see citing works

Too Many 'Too Young to Be Vaccinated': An Observational Cohort and Case-Control Study of 4CMenB Vaccine Effectiveness and Impact Against Serogroup B Meningococcal Disease in ItalyPreprint

Lodi, L., Barbati, F., Amicizia, D., Baldo, V., Barbui, A. M., Bondi, A., Costantino, C., Dadalt, L., Ferrara, L., Fortunato, F., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4366840

P-1498. Real-World Vaccine Effectiveness and Impact of the 4CMenB Vaccine in Infants, Children, and Adolescents: A Systematic Literature Review

Marijic, P., Gaianu, L., Mathur, G., Pinto, T., Andani, A., Ladak, R., Kuylen, E., Szewczyk, K., Olewinska, E., Smela, B., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf695.1682